Serotonin levels and 1-year mortality in patients with neuroendocrine tumors: a systematic review and meta-analysis. (8th February 2019)

• Record Type: Journal Article
• Authors: Joish, Vijay N; Shah, Sandip; Tierce, Jonothan C; Patel, Deep; McKee, Chad; Lapuerta, Pablo; Zacks, Jerome
• Is Part Of: Future oncology. Volume 15:Number 12(2019)
• Page Start: 1397
• Page End: 1406
• Publication Date: 2019-02-08
• Subjects: carcinoid syndrome -- mortality -- neuroendocrine tumors -- serotonin; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2018-0960
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: Elevated serotonin in patients with neuroendocrine tumors (NETs) may impact heart failure incidence but a quantitative relationship has not been established.Materials & methods: Systematic review and meta-analysis of studies assessing 24-h urinary 5-hydroxyindoleacetic acid (u5-HIAA) and mortality in patients with NETs (2007–2017) with a primary outcome of 1-year mortality risk and 24-h u5-HIAA.Results: We identified 1715 records of which 12 studies including 755 patients (3442 person-years with 376 deaths) were eligible for meta-analysis. Mean u5-HIAA was 149.2 mg/24 h (standard deviation: 96.6) and mortality was 13.0%. The meta-regression equation showed an 11.8% (95% CI: 8.9–17.0%; I 2 = 93.0%) increase in 1-year mortality for every ten-unit increase in u5-HIAA.Conclusion: Serotonin measured by its metabolite u5-HIAA is predictive of 1-year all-cause mortality in patients with NETs.